All In Biotech

Drug Trial Radar · NCT04539496

A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors

A Multicenter, Open-label Phase I/II Study of XZP-3287 in Metastasis Solid Tumors in China

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

402

Actual

Start

May 22, 2018

Primary completion

Jul 31, 2023

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study includes single agent/combination dose exploration study and the phase II study. The primary purpose of the dose exploration study is to determine the maximum tolerated dose(MTD)/recommended phase II dose(RP2D) of XZP-3287 and assess its safety and preliminary efficacy in solid tumor patients. The phase II study aims to explore the efficacy and safety profiles of XZP-3287 as a single- agent in hormone receptor(HR) positive, human epidermal growth factor receptor 2(HER2) negative advanced breast cancer.

Conditions

  • Metastasis Solid Tumors
  • Advanced Breast Cancer

Interventions

  • XZP-3287Drug

    * 20-560 mg QD, oral * 240-480 mg BID, oral

  • XZP-3287;Letrozole;Anastrozole;FulvestrantDrug

    XZP-3287: 360 mg BID, oral; Letrozole: 2.5 mg QD, oral; Anastrozole: 1 mg QD, oral; Fulvestrant: 500 mg intramuscular injection on C1D1, C1D15, the first day of each subsequent cycle (28 days a cycle)

  • XZP-3287Drug

    480 mg BID, oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single agent and combination dose exploration study:AE evaluationTime frame: Up to 30 days after the end of treatment
  2. The phase II study:Objective response rate (ORR) assessed by Independent Review Committee (IRC)Time frame: From baseline to the date of first documentation of progression or death , whichever came first, assessed approximately up to 2 years after the last entered participant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.